NanoViricides Inc (NYSEAMERICAN:NNVC) saw a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 137,100 shares, a drop of 6.5% from the September 30th total of 146,600 shares. Currently, 5.0% of the shares of the stock are sold short. Based on an average daily volume of 42,700 shares, the short-interest ratio is presently 3.2 days.

Shares of NNVC opened at $2.15 on Monday. NanoViricides has a 12 month low of $1.27 and a 12 month high of $13.60.

NanoViricides Company Profile

NanoViricides, Inc, a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as injectable and oral anti-influenza nanoviricide drug for H7N9, Bird Flu H5N1, other Highly Pathogenic Influenzas, Epidemic Influenzas, and Seasonal Influenzas; DengueCide, an anti-dengue nanoviricide which is in pre-clinical development; and HIVCide, an anti-human immunodeficiency virus drug candidate.

Further Reading: What is the formula for calculating total return?

Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.